Adicet Bio (ACET) risk factors
Item 1A of every Adicet Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors106 risks6 new5 dropped27 reworded
Adicet restructured its workforce and added $2.3 million in severance costs while updating its clinical pipelines and regulatory timelines. The company faces new constraints regarding foreign data acceptance, AI data breaches, and China data transmission measures. Drug pricing legislative pressure increased under the Inflation Reduction Act and new tax laws like OBBBA.
Filed Mar 12, 2026 - FY2024 10-K risk factors105 risks
Adicet faces significant clinical and regulatory risks developing novel allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Substantial ongoing net losses, capital needs, and complex manufacturing or supply chain constraints threaten commercial viability. Operations and contractual VIE structures in China introduce severe geopolitical, regulatory, and data compliance risks.
Filed Mar 06, 2025